Kent Town, Australia, December 19, 2012 --(PR.com
)-- Wescadia Group, a healthcare consultancy firm, announces the release of its report “BioDeal 360™”. The purpose of the report is to provide an overview of selected deals such as in-licensing, out-licensing or mergers and acquisitions (M&A) by Australian life science companies over the last 12 months and to understand the strategic significance of the deals.
“Our profiles of the deals entered into by Australian life science companies shows that their innovative technologies have a pivotal role in meeting the strategic needs of their partners,” said Marcus Bain, Ph.D., managing director of Wescadia Group.
· Which pharmaceutical, biotechnology, medical device and diagnostic players in Australia have been active in deals? What are the reasons for the different level of deal activity between the different players?
· What is the rationale for transactions between Australian life science companies and their partners? What approaches maximize the value of transactions between Australian life science companies and their partners?
· How can Australian life science companies capitalize on the challenges facing big pharma?
Sienna Cancer Diagnostics
Specialised Therapeutics Australia
For more information on the report or to order a copy, please visit us at http://wescadiagroup.com/free-resources/biodeal-360/.
About Wescadia Group
Wescadia Group is a healthcare consultancy firm that works with life science organizations to help them achieve sustainable growth, bring innovative treatments to market and maximize the value of their assets.
Wescadia Group Pty Ltd (ABN 26.156.459.504)
Phone: +61. 8.8125.5820